Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ArQule provides update on early-stage product pipeline
The FDA has accepted an investigational new drug application (IND) for ARQ 621, and the company plans to initiate a Phase I clinical trial with this compound in
The FDA has accepted an investigational new drug application (IND) for ARQ 621, and the company plans to initiate a Phase I clinical trial with this compound in
Under the terms of the agreement, AstraZeneca is expected to pay Map Pharmaceuticals an upfront cash payment of $40m and an additional $35m upon the successful achievement of primary endpoint
The Phase I clinical trial of ICT-107 was conducted to evaluate the safety and tolerability of the cancer vaccine in patients with glioblastoma, the most common and malignant
Under the terms of the agreement, the license grants exclusive rights to Drais to develop and commercialize DTS-108 worldwide. In return, Diatos is expected to receive an upfront payment, development
The newly approved combination therapy between Fastic or Starsis tablet (nateglinide) that suppresses elevation of postprandial blood glucose levels and thiazolidines that improve insulin resistance has already been
China Biologic has received sales orders on all the products that have been registered under the Central Drugs Standard Control Organization, the drug control administration in India. Those
NGX-4010 is a dermal high-concentration capsaicin patch designed to provide rapid, localized and sustained pain relief in patients with post-herpetic neuralgia (PHN). The company also announced that it
Daiichi Sankyo and The Kitasato Institute’s Research Organization for Infection Control Sciences will discover and develop vaccine seeds together and proactively obtain licenses and technologies from third parties
Under terms of the acquisition agreement, Volcano will pay approximately $21.5 million in cash at closing, which is expected to occur in late December 2008. Axsun will operate
Under the terms of the agreement, Forest is expected to make an upfront payment to Pierre Fabre of $75m and will pay future, undisclosed milestone payments. In addition, Pierre Fabre